The history of Viagra presents a complex picture for investors. While the initial release generated massive profits, the expiration of its intellectual property protection opened the floodgates to cheaper versions, dramatically reducing sales. This poses a unique challenge for pharmaceutical companies depending on related blockbuster medications, s

The story of Viagra, and its parent company copyright, presents a intriguing case study for investors. Originally a blockbuster drug, producing billions in income, its exclusivity period created a wave of lower-priced alternatives , significantly diminishing its dominance. While some pharmaceutical companies may try to capitalize on similar conditi